Using a lipopolysaccharide-induced acute lung injury mouse model, they found that FZJDF treatment alleviated intestinal barrier dysfunction, reduced systemic and pulmonary inflammation, and attenuated lung histopathological changes, which were associated with the regulation of key signaling pathways, such as NF-κB and MAPK, in both the gut and the lung. Here, NFKB1 is linked to injury.